Keith McBurnett

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi Structure and validity of sluggish cognitive tempo using an expanded item pool in children with attention-deficit/hyperactivity disorder
    Keith McBurnett
    University of California, San Francisco, San Francisco, CA, USA
    J Abnorm Child Psychol 42:37-48. 2014
  2. ncbi Pharmacotherapy of inattention and ADHD in adolescents
    Keith McBurnett
    University of California, San Francisco, USA
    Adolesc Med State Art Rev 24:391-405, viii. 2013
  3. doi OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder
    Keith McBurnett
    Department of Psychiatry, University of California San Francisco, 401 Parnassus Avenue, San Francisco, CA 94143, USA
    Expert Opin Pharmacother 12:315-24. 2011
  4. ncbi Mood and hormone responses to psychological challenge in adolescent males with conduct problems
    Keith McBurnett
    Department of Psychiatry, University of California San Francisco, Langley Porter Psychiatric Institute, California 94146, USA
    Biol Psychiatry 57:1109-16. 2005
  5. doi Treatment of aggressive ADHD in children and adolescents: conceptualization and treatment of comorbid behavior disorders
    Keith McBurnett
    Department of Psychiatry, University of California, San Francisco, CA 94143, USA
    Postgrad Med 121:158-65. 2009
  6. ncbi Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder
    Richard Weisler
    Department of Psychiatry, University of North Carolina, Chapel Hill, USA
    CNS Spectr 14:573-85. 2009
  7. ncbi Family correlates of comorbid anxiety disorders in children with attention deficit/hyperactivity disorder
    Linda J Pfiffner
    Department of Psychiatry Children s Center at Langley Porter, University of California, San Francisco, CA 94143, USA
    J Abnorm Child Psychol 34:725-35. 2006
  8. ncbi Family correlates of oppositional and conduct disorders in children with attention deficit/hyperactivity disorder
    Linda J Pfiffner
    Department of Psychiatry, University of California, San Francisco, California 94143, USA
    J Abnorm Child Psychol 33:551-63. 2005
  9. doi Child ADHD severity and positive and negative parenting as predictors of child social functioning: evaluation of three theoretical models
    Nina M Kaiser
    Department of Psychiatry, University of California, San Francisco, CA, USA
    J Atten Disord 15:193-203. 2011
  10. ncbi Waxing and waning in concert: dynamic comorbidity of conduct disorder with other disruptive and emotional problems over 7 years among clinic-referred boys
    Benjamin B Lahey
    Department of Psychiatry, University of Chicago, Illinois 60637, USA
    J Abnorm Psychol 111:556-67. 2002

Detail Information

Publications24

  1. doi Structure and validity of sluggish cognitive tempo using an expanded item pool in children with attention-deficit/hyperactivity disorder
    Keith McBurnett
    University of California, San Francisco, San Francisco, CA, USA
    J Abnorm Child Psychol 42:37-48. 2014
    ..SCT appears to be meaningfully associated with impairment, even when controlling for depression. Common behaviors resembling Working Memory problems may represent a previously undescribed factor of SCT...
  2. ncbi Pharmacotherapy of inattention and ADHD in adolescents
    Keith McBurnett
    University of California, San Francisco, USA
    Adolesc Med State Art Rev 24:391-405, viii. 2013
    ..Such inferences, in the face of literature gaps, in no way obviate the need for continued research focused on adolescence...
  3. doi OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder
    Keith McBurnett
    Department of Psychiatry, University of California San Francisco, 401 Parnassus Avenue, San Francisco, CA 94143, USA
    Expert Opin Pharmacother 12:315-24. 2011
    ..Impairment across multiple domains of daily living can be mild to serious. OROS methylphenidate (MPH) was evaluated in two large adult clinical trials, and in 2008 it was approved in the USA to treat ADHD in adults aged up to 65 years...
  4. ncbi Mood and hormone responses to psychological challenge in adolescent males with conduct problems
    Keith McBurnett
    Department of Psychiatry, University of California San Francisco, Langley Porter Psychiatric Institute, California 94146, USA
    Biol Psychiatry 57:1109-16. 2005
    ..Relations between stress hormones and antisocial behavior are understudied...
  5. doi Treatment of aggressive ADHD in children and adolescents: conceptualization and treatment of comorbid behavior disorders
    Keith McBurnett
    Department of Psychiatry, University of California, San Francisco, CA 94143, USA
    Postgrad Med 121:158-65. 2009
    ....
  6. ncbi Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder
    Richard Weisler
    Department of Psychiatry, University of North Carolina, Chapel Hill, USA
    CNS Spectr 14:573-85. 2009
    ..To evaluate the long-term safety and effectiveness of lisdexamfetamine dimesylate (LDX) in the treatment of adults with attention-deficit/hyperactivity disorder (ADHD)...
  7. ncbi Family correlates of comorbid anxiety disorders in children with attention deficit/hyperactivity disorder
    Linda J Pfiffner
    Department of Psychiatry Children s Center at Langley Porter, University of California, San Francisco, CA 94143, USA
    J Abnorm Child Psychol 34:725-35. 2006
    ..These findings are consistent with theory linking those three family factors to the development of anxiety in all children. Implications for adjunctive treatment of anxiety that is comorbid with ADHD are discussed...
  8. ncbi Family correlates of oppositional and conduct disorders in children with attention deficit/hyperactivity disorder
    Linda J Pfiffner
    Department of Psychiatry, University of California, San Francisco, California 94143, USA
    J Abnorm Child Psychol 33:551-63. 2005
    ..Efforts to prevent and/or treat CD should consider not only provision of structure and prudent discipline, but also the affective qualities of the relationship between the primary caretaker and child...
  9. doi Child ADHD severity and positive and negative parenting as predictors of child social functioning: evaluation of three theoretical models
    Nina M Kaiser
    Department of Psychiatry, University of California, San Francisco, CA, USA
    J Atten Disord 15:193-203. 2011
    ....
  10. ncbi Waxing and waning in concert: dynamic comorbidity of conduct disorder with other disruptive and emotional problems over 7 years among clinic-referred boys
    Benjamin B Lahey
    Department of Psychiatry, University of Chicago, Illinois 60637, USA
    J Abnorm Psychol 111:556-67. 2002
    ..These findings indicate a striking degree of dynamic comorbidity between CD and other types of psychopathology and provide an initial empirical framework for needed developmental models of comorbidity...
  11. ncbi Additive effects of parent adherence on social and behavioral outcomes of a collaborative school-home behavioral intervention for ADHD
    MIGUEL T VILLODAS
    Department of Psychiatry, University of California, San Francisco, 401 Parnassus Ave, Box 0984 CAS, San Francisco, CA, 94143, USA
    Child Psychiatry Hum Dev 45:348-60. 2014
    ..Findings support the emphasis of CLS on coordinating intervention strategies across contexts to facilitate the generalization of treatment-related improvements in social and behavioral functioning. ..
  12. pmc Educational outcomes of a collaborative school-home behavioral intervention for ADHD
    Linda J Pfiffner
    Department of Psychiatry, University of California, San Francisco, San Francisco, CA 94143, USA
    Sch Psychol Q 28:25-36. 2013
    ..Findings support the focus of CLS on both ADHD symptom reduction and organizational skill improvement and support the feasibility of a model which utilizes school-based mental health professionals as providers...
  13. pmc Prevention of serious conduct problems in youth with attention deficit/hyperactivity disorder
    MIGUEL T VILLODAS
    Department of Psychiatry, University of California, San Francisco, CA 94143, USA
    Expert Rev Neurother 12:1253-63. 2012
    ..Future directions for researchers are discussed...
  14. ncbi A randomized, controlled trial of integrated home-school behavioral treatment for ADHD, predominantly inattentive type
    Linda J Pfiffner
    Department of Psychiatry, University of California, San Francisco, USA
    J Am Acad Child Adolesc Psychiatry 46:1041-50. 2007
    ..To evaluate the efficacy of a behavioral psychosocial treatment integrated across home and school (Child Life and Attention Skills Program) with attention-deficit/hyperactivity disorder (ADHD) predominantly inattentive type (ADHD-I)...
  15. ncbi Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder
    Lenard A Adler
    Department of Psychiatry, New York University School of Medicine, 530 First Ave 7D, New York, NY 10016, USA
    J Clin Psychiatry 69:1364-73. 2008
    ..To evaluate the efficacy and safety of 30, 50, and 70 mg/day lisdexamfetamine dimesylate compared with placebo in adults with attention-deficit/hyperactivity disorder (ADHD)...
  16. ncbi Acetyl-L-carnitine (ALC) in attention-deficit/hyperactivity disorder: a multi-site, placebo-controlled pilot trial
    L Eugene Arnold
    The Ohio State University Nisonger Center, Columbus, OH, USA
    J Child Adolesc Psychopharmacol 17:791-802. 2007
    ..Trials in Down's syndrome, migraine, and Alzheimer's disease showed benefit for attention. A preliminary trial in ADHD using L-carnitine reported significant benefit...
  17. ncbi ADHD subtype differences in motivational responsivity but not inhibitory control: evidence from a reward-based variation of the stop signal paradigm
    Cynthia L Huang-Pollock
    Department of Psychology, Pennsylvania State University, University Park, PA 16802 3106, USA
    J Clin Child Adolesc Psychol 36:127-36. 2007
    ....
  18. ncbi ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study
    Timothy Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, 15 Parkman Street, Boston, MA 02114, USA
    J Am Acad Child Adolesc Psychiatry 42:424-33. 2003
    ..This article reports an interim analysis of a 24-month study evaluating the 12-month tolerability and effectiveness of a once-daily OROS formulation of methylphenidate (OROS MPH) in children with ADHD...
  19. ncbi The reliability and validity of Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version- Korean version (K-SADS-PL-K)
    Young Shin Kim
    Division of Child and Adolescent Psychiatry, Department of Psychiatry, Hallym University Sacred Heart Hospital, Anyang, Korea
    Yonsei Med J 45:81-9. 2004
    ..Future studies will examine the validity and reliability of the K-SADS-PL-K in larger samples, including adolescents and community samples on a variety of child and adolescent psychiatric disorders...
  20. ncbi ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study
    Timothy Wilens
    Massachusetts General Hospital, Pediatric Psychopharmacology, Boston, MA 02114, USA
    J Am Acad Child Adolesc Psychiatry 44:1015-23. 2005
    ..This article presents final results from an open-label, multisite study of a once-daily formulation of methylphenidate (MPH), OROS MPH...
  21. ncbi Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder
    Timothy E Wilens
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, YAW 6 6A, 32 Fruit Street, Boston, MA 02114, USA
    Arch Pediatr Adolesc Med 160:82-90. 2006
    ..Despite the persistence of attention-deficit/hyperactivity disorder (ADHD) into adolescence, little is known about the efficacy and tolerability of stimulant medications in this age group...
  22. ncbi Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder
    James J McGough
    Semel Institute for Neuroscience and Human Behavior, and David Geffen School of Medicine at UCLA, 300 UCLA Medical Plaza, Los Angeles, CA 90095, USA
    J Child Adolesc Psychopharmacol 16:351-6. 2006
    ..Headache, anorexia, and insomnia were the most frequently reported treatment-related adverse events. The incidence of adverse events was not related to dose. OROS MPH was safe and well tolerated at doses up to 72 mg/day...
  23. ncbi Social skills differences among attention-deficit/hyperactivity disorder types in a chat room assessment task
    Amori Yee Mikami
    Department of Psychology, University of Virginia, 102 Gilmer Hall, P O Box 400400, Charlottesville, VA 22904 4400, USA
    J Abnorm Child Psychol 35:509-21. 2007
    ..SCT symptoms, most prevalent among children with ADHD-I, predicted a distinct pattern of social withdrawal and lower hostility. Parent and teacher ratings and in-vivo observations of social skills correlate with this new measure...
  24. doi A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder
    Joseph Biederman
    Pediatric Psychopharmacology Department, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Pediatrics 121:e73-84. 2008
    ..With this study we assessed the efficacy and safety of an extended-release formulation of guanfacine compared with placebo for the treatment of children and adolescents with attention-deficit/hyperactivity disorder...